SG11201810323RA - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- SG11201810323RA SG11201810323RA SG11201810323RA SG11201810323RA SG11201810323RA SG 11201810323R A SG11201810323R A SG 11201810323RA SG 11201810323R A SG11201810323R A SG 11201810323RA SG 11201810323R A SG11201810323R A SG 11201810323RA SG 11201810323R A SG11201810323R A SG 11201810323RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pheny1
- manchester
- lankro
- obh
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609222.3A GB201609222D0 (en) | 2016-05-25 | 2016-05-25 | Pharmaceutical formulation |
| PCT/GB2017/051494 WO2017203270A1 (fr) | 2016-05-25 | 2017-05-25 | Préparation pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810323RA true SG11201810323RA (en) | 2018-12-28 |
Family
ID=56369959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810323RA SG11201810323RA (en) | 2016-05-25 | 2017-05-25 | Pharmaceutical formulation |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10973821B2 (fr) |
| EP (1) | EP3463365B1 (fr) |
| JP (1) | JP7141108B2 (fr) |
| KR (1) | KR102464150B1 (fr) |
| CN (1) | CN109982704B (fr) |
| AU (1) | AU2017270942B2 (fr) |
| BR (1) | BR112018074162A2 (fr) |
| CA (1) | CA3024771A1 (fr) |
| CY (1) | CY1124733T1 (fr) |
| DK (1) | DK3463365T3 (fr) |
| ES (1) | ES2888951T3 (fr) |
| GB (1) | GB201609222D0 (fr) |
| HR (1) | HRP20211795T1 (fr) |
| HU (1) | HUE056129T2 (fr) |
| IL (1) | IL263167B (fr) |
| LT (1) | LT3463365T (fr) |
| MA (1) | MA45126A (fr) |
| MX (1) | MX2018014232A (fr) |
| MY (1) | MY197663A (fr) |
| PL (1) | PL3463365T3 (fr) |
| PT (1) | PT3463365T (fr) |
| RU (1) | RU2760681C2 (fr) |
| SG (1) | SG11201810323RA (fr) |
| SI (1) | SI3463365T1 (fr) |
| WO (1) | WO2017203270A1 (fr) |
| ZA (1) | ZA201807851B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609222D0 (en) * | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| CN113429396A (zh) * | 2021-06-08 | 2021-09-24 | 深圳市祥根生物医药有限公司 | 一种五元杂芳环衍生物及其制备方法和用途 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1051723A (fr) | 1962-04-27 | |||
| US3202654A (en) | 1962-04-27 | 1965-08-24 | Bristol Myers Co | 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof |
| US3252970A (en) | 1963-02-27 | 1966-05-24 | Ciba Geigy Corp | Aromatization |
| BE631632A (fr) | 1963-04-26 | |||
| US3268558A (en) | 1964-11-05 | 1966-08-23 | Ortho Pharma Corp | 1-r-2, 4-dinitropyrroles |
| US3458515A (en) | 1966-07-21 | 1969-07-29 | American Home Prod | Piperazine substituted pyrroles |
| GB1208014A (en) | 1967-03-23 | 1970-10-07 | Glaxo Lab Ltd | Cephalosporins |
| US3573294A (en) | 1968-03-14 | 1971-03-30 | Glaxo Lab Ltd | 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives |
| BE790747A (fr) | 1971-10-30 | 1973-02-15 | Whitefin Holding Sa | Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation |
| GB1476503A (en) | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| BE848465A (fr) | 1976-11-18 | 1977-03-16 | Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent | |
| US4316900A (en) | 1977-10-05 | 1982-02-23 | Ciba-Geigy Corporation | Piperazinopyrrolobenzodiazepines |
| JPS57142966A (en) | 1981-02-27 | 1982-09-03 | Sagami Chem Res Center | (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative |
| JPS57144255A (en) | 1981-03-03 | 1982-09-06 | Sagami Chem Res Center | Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative |
| US4761424A (en) | 1985-10-01 | 1988-08-02 | Warner-Lambert Company | Enolamides, pharmaceutical compositions and methods for treating inflammation |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5637592A (en) | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
| HUT77867A (hu) | 1994-07-21 | 1998-09-28 | Eli Lilly And Co. | sPLA2-gátló indolizinszármazékok és az ezeket tartalmazó gyógyszerkészítmények |
| KR19990008109A (ko) | 1995-04-28 | 1999-01-25 | 나가사까 겐지로 | 1,4-이치환 피페리딘 유도체 |
| DE69517160T2 (de) | 1995-06-06 | 2000-11-16 | Agfa-Gevaert N.V., Mortsel | Photographische Materialien |
| JPH09249669A (ja) | 1996-03-13 | 1997-09-22 | Ono Pharmaceut Co Ltd | 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤 |
| JP4439596B2 (ja) | 1997-06-13 | 2010-03-24 | サイデクス ファーマシューティカルズ、 インク． | 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法 |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| JP4722288B2 (ja) | 1998-06-03 | 2011-07-13 | ジーピーアイ ニル ホールディングス インコーポレイテッド | 神経学上の傷害および毛髪損失を治療するために使用されるａｚａ−複素環式化合物 |
| ATE404178T1 (de) | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| EA200101172A1 (ru) | 1999-05-04 | 2002-04-25 | Янссен Фармацевтика Н.В. | Противогрибковые эфиры |
| WO2001008572A1 (fr) | 1999-07-30 | 2001-02-08 | Norbert Heske | Systeme de canule permettant l'introduction d'instruments endoscopiques dans un corps humain ou animal |
| EP1712222A3 (fr) | 1999-12-23 | 2012-06-20 | Pfizer Products Inc. | Compositions pharmaceutiques fournissant des concentrations de médicaments améliorées |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| US7202239B2 (en) | 2001-04-12 | 2007-04-10 | Wyeth | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists |
| US6825201B2 (en) | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| WO2002098876A1 (fr) | 2001-06-06 | 2002-12-12 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de cak et leurs utilisations |
| EP1405852B9 (fr) | 2001-06-20 | 2013-03-27 | Daiichi Sankyo Company, Limited | Derives de diamine |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| WO2003063822A2 (fr) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie |
| CA2474958A1 (fr) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen de buses de projection |
| EP1476163A4 (fr) | 2002-02-23 | 2009-05-27 | Bristol Myers Squibb Co | Procede de traitement de l'infection par le vih consistant a eviter toute interaction du cd4 et du gp120 |
| CN100518831C (zh) | 2002-08-15 | 2009-07-29 | 刘云清 | 固体纳米药物及其制备方法 |
| US20050032871A1 (en) | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| AU2004222387A1 (en) | 2003-03-13 | 2004-09-30 | Synta Pharmaceuticals Corp. | Fused pyrrole compounds |
| FR2854079B1 (fr) | 2003-04-25 | 2007-11-30 | Pf Medicament | Procede de preparation de complexes moleculaires |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| RU2006117635A (ru) | 2003-10-24 | 2007-12-10 | Шеринг Акциенгезельшафт (De) | Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование |
| EP1753402B1 (fr) | 2004-05-28 | 2008-10-01 | Pfizer Products Incorporated | Compositions pharmaceutiques aux performances accrues comprenant un polymère hpmca |
| US20060058286A1 (en) | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| EP2548894A1 (fr) | 2005-02-03 | 2013-01-23 | Bend Research, Inc. | Compositions pharmaceutiques à éfficacité améliorée |
| AU2006230364B2 (en) | 2005-03-31 | 2012-09-13 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| NZ563397A (en) | 2005-05-18 | 2010-04-30 | F2G Ltd | Antifungal agents comprising indolizinyl derivatives |
| CA2613458A1 (fr) | 2005-07-12 | 2007-01-18 | Acadia Pharmaceuticals Inc. | Composes presentant une activite au niveau des recepteurs de l'acide retinoique |
| WO2007015866A2 (fr) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibiteurs de la p38 kinase et procédés de traitement d’affections inflammatoires |
| TW201414469A (zh) | 2006-03-20 | 2014-04-16 | Vertex Pharma | 對包括ｖｘ-９５０之藥物實施噴霧乾燥之方法及由此方法製備之產物 |
| US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
| US20080118500A1 (en) | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| GB0623209D0 (en) | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| EP2125938A2 (fr) | 2007-01-26 | 2009-12-02 | Isp Investments Inc. | Procédé de traitement de formulation pour produire des produits séchés pour une pulvérisation |
| CN101260086B (zh) | 2007-03-06 | 2011-08-10 | 中国科学院上海药物研究所 | 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途 |
| GB0710121D0 (en) | 2007-05-25 | 2007-07-04 | F2G Ltd | Antifungal agents |
| WO2009010842A2 (fr) | 2007-07-13 | 2009-01-22 | Pfizer Products Inc. | Nanoparticules comprenant des polymères cellulosiques ionisables faiblement solubles dans l'eau |
| JP5657524B2 (ja) * | 2008-04-24 | 2015-01-21 | エフツージー リミテッド | ピロール抗真菌剤 |
| GB0809773D0 (en) | 2008-05-29 | 2008-07-09 | F2G Ltd | Antifungal combination therapy |
| US20100093872A1 (en) | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| EA201101568A1 (ru) | 2009-04-28 | 2012-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta |
| US9040033B2 (en) | 2010-06-14 | 2015-05-26 | Dow Global Technologies Llc | Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution |
| WO2012031129A2 (fr) | 2010-09-03 | 2012-03-08 | Bend Research, Inc. | Appareil de séchage par pulvérisation et ses procédés d'utilisation |
| JPWO2012060448A1 (ja) | 2010-11-05 | 2014-05-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗真菌剤としての併用医薬組成物 |
| US20120308662A1 (en) | 2011-06-01 | 2012-12-06 | Nitto Denko Corporation | Particulate preparation and method for producing the same |
| KR101922752B1 (ko) | 2011-11-29 | 2018-11-27 | 주록스 피티와이 리미티드 | 사이클로덱스트린 및 소수성 약물을 포함하는 주사용 약제학적 조성물을 보존하는 방법 |
| WO2013154607A1 (fr) | 2012-04-11 | 2013-10-17 | Dow Global Technologies Llc | Éthers de cellulose estérifiés ayant une distribution de substituants spécifique |
| EP2888293B1 (fr) | 2012-08-24 | 2019-05-08 | Dow Global Technologies LLC | Nouveaux acétate-succinates d'hydroxyalkylméthylcellulose |
| EP2888289B1 (fr) | 2012-08-24 | 2019-08-07 | Dow Global Technologies LLC | Ethers de cellulose estérifiés partiellement réticulés |
| WO2014114575A1 (fr) | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Composition pharmaceutique à biodisponibilité ameliorée |
| CN105377235A (zh) | 2013-07-19 | 2016-03-02 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
| WO2015007759A1 (fr) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Composition pharmaceutique aqueuse liquide contenant des dérivés de cyclodextrine éthérifiée |
| US20160303102A1 (en) | 2013-12-05 | 2016-10-20 | Alrise Biosystems Gmbh | Process for the production of drug formulations for oral administration |
| PT107568B (pt) | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
| JP6681894B2 (ja) | 2014-11-21 | 2020-04-15 | エフツージー リミテッド | 抗真菌剤 |
| GB201609222D0 (en) * | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
-
2016
- 2016-05-25 GB GBGB1609222.3A patent/GB201609222D0/en not_active Ceased
-
2017
- 2017-05-25 HR HRP20211795TT patent/HRP20211795T1/hr unknown
- 2017-05-25 IL IL263167A patent/IL263167B/en unknown
- 2017-05-25 ES ES17728590T patent/ES2888951T3/es active Active
- 2017-05-25 WO PCT/GB2017/051494 patent/WO2017203270A1/fr active Search and Examination
- 2017-05-25 LT LTEPPCT/GB2017/051494T patent/LT3463365T/lt unknown
- 2017-05-25 CN CN201780046136.8A patent/CN109982704B/zh active Active
- 2017-05-25 RU RU2018142381A patent/RU2760681C2/ru active
- 2017-05-25 SI SI201730974T patent/SI3463365T1/sl unknown
- 2017-05-25 EP EP17728590.5A patent/EP3463365B1/fr active Active
- 2017-05-25 BR BR112018074162-0A patent/BR112018074162A2/pt unknown
- 2017-05-25 HU HUE17728590A patent/HUE056129T2/hu unknown
- 2017-05-25 MX MX2018014232A patent/MX2018014232A/es unknown
- 2017-05-25 MA MA045126A patent/MA45126A/fr unknown
- 2017-05-25 DK DK17728590.5T patent/DK3463365T3/da active
- 2017-05-25 SG SG11201810323RA patent/SG11201810323RA/en unknown
- 2017-05-25 JP JP2018561686A patent/JP7141108B2/ja active Active
- 2017-05-25 MY MYPI2018002103A patent/MY197663A/en unknown
- 2017-05-25 KR KR1020187037061A patent/KR102464150B1/ko active IP Right Grant
- 2017-05-25 PL PL17728590T patent/PL3463365T3/pl unknown
- 2017-05-25 US US16/303,999 patent/US10973821B2/en active Active
- 2017-05-25 PT PT177285905T patent/PT3463365T/pt unknown
- 2017-05-25 AU AU2017270942A patent/AU2017270942B2/en active Active
- 2017-05-25 CA CA3024771A patent/CA3024771A1/fr active Pending
-
2018
- 2018-11-21 ZA ZA2018/07851A patent/ZA201807851B/en unknown
-
2021
- 2021-03-01 US US17/189,091 patent/US20210186967A1/en not_active Abandoned
- 2021-11-19 CY CY20211101000T patent/CY1124733T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201810323RA (en) | Pharmaceutical formulation | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201807023QA (en) | Compositions and methods for preventing and/or treating vitamin b12 deficiency |